Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A9 | P06702 | 2/20 | 0.60 |
| ▸ | CCR4 | P51679 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16234982 | 0.93 | S100A9 (0.68) | S100A9CCR4MEN1KMT2APOLB | |
| SCHEMBL16235973 | 0.78 | S100A9 (0.53) | S100A9CCR4KMT2AHTT | |
| SCHEMBL16235038 | 0.77 | S100A9 (0.61) | S100A9CCR4HTT | |
| SCHEMBL16235057 | 0.76 | ACLY (0.47) | S100A9CCR4POLBAPLNRHTT | |
| SCHEMBL16234996 | 0.76 | S100A9 (1.00) | S100A9CCR4KDM1AMAOA | |
| SCHEMBL16235782 | 0.75 | ALDH1A1 (0.53) | S100A9CCR4MEN1KMT2APOLB | |
| SCHEMBL16235072 | 0.74 | S100A9 (0.45) | S100A9CCR4KMT2AHTT | |
| SCHEMBL16235255 | 0.73 | S100A9 (0.53) | S100A9CCR4MEN1KMT2APOLB | |
| SCHEMBL16235121 | 0.72 | ALDH1A1 (0.50) | CCR4MEN1KMT2AHTTMAPT | |
| SCHEMBL2220791 | 0.71 | FYN (0.42) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | S100A9 1/4885CCR4 4428/4885MEN1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.